Co-morbidities

Andrew McRae ,

Read time: 10 Mins

Desak Ketut Sekar Cempaka Putri , Andrianto Andrianto , Makhyan Jibril Al-Farabi , et al

Read time: 16 Mins

Stefan Anker, Javed Butler, Antonio Ceriello, et al

Stefan Anker, Javed Butler, Antonio Ceriello, et al

Maria Stefil , Matthew Dixon , Jameela Bahar , et al

Read time: 21 Mins

Andrew JS Coats,

Silvio Inzucchi, Andrew JS Coats, Richard Hobbs, et al

Radcliffe & CardioNerds @AHA22: EMPA-Kidney: Empagliflozin & CV Outcomes in Patients with Chronic Kidney Disease

Kate Wilcox, David Preiss,

Watch time: 18m

Paul Kalra,

Watch time: 12m 40s (2 videos)

Christiane Angermann, Javed Butler, Clyde W Yancy, et al

Watch time: 1h 4m (6 videos)

Giuseppe Rosano, Richard Henry P Tiongco, Rungroj Krittayaphong, et al

Mauro Gori , Emilia D’Elia , Edoardo Sciatti , et al

Philippe Pibarot, Patrizio Lancellotti, Jose Luis Zamorano, et al

Christiane Angermann, Javed Butler, Clyde W Yancy, et al

Watch time: 1h 4m (6 videos)

Piotr Ponikowski, Shelley Zieroth, Javed Butler, et al

Watch time: 1h 3m (4 videos)

Giuseppe Rosano , David Quek , Felipe Martínez ,

John JV McMurray, Stefan Anker, Melanie Davies, et al

Stephen Fishbane, Adeera Levin, Kieran McCafferty , et al

Stefan Anker, Shelley Zieroth, Andrew JS Coats, et al

Shelley Zieroth, Martin R Cowie, Javed Butler, et al

Effects of Dapagliflozin in Patients With Chronic Kidney Disease, With and Without Heart Failure

John JV McMurray,

The PRESERVED-HF Study – Main Study Presentation and Peer-to-peer Discussion

Mikhail Kosiborod, Dalane W Kitzman,

Carol Pollock, Mark Petrie, David Cherney , et al

Shelley Zieroth, Kamlesh Khunti, Hiddo Lambers Heerspink, et al

About

Comorbidities frequently accompany chronic heart failure, contributing to increased morbidity and mortality, and an impaired quality of life. Extreme comorbidity is significantly more common in patients with chronic heart failure due to left ventricular systolic dysfunction. The efficient management of such complexity requires the integration of general and specialist expertise.

Media

Stefan Anker, Javed Butler, Antonio Ceriello, et al

Stefan Anker, Javed Butler, Antonio Ceriello, et al

Silvio Inzucchi, Andrew JS Coats, Richard Hobbs, et al

Paul Kalra,

Watch time: 12m 40s (2 videos)

Christiane Angermann, Javed Butler, Clyde W Yancy, et al

Watch time: 1h 4m (6 videos)

Giuseppe Rosano, Richard Henry P Tiongco, Rungroj Krittayaphong, et al

Piotr Ponikowski, Shelley Zieroth, Javed Butler, et al

Watch time: 1h 3m (4 videos)

Andrew JS Coats, Stefan Anker,

Watch Now

Carlos Juanatey,

Watch Now

Stylianos Tzeis,

Watch Now

Yassir Javaid,

Effects of Dapagliflozin in Patients With Chronic Kidney Disease, With and Without Heart Failure

John JV McMurray,

Lars H Lund, James L Januzzi, Justin Ezekowitz, et al

EMPATROPISM FE: Effects of Empagliflozin on iron metabolism in non-diabetic

Christiane Angermann,

Shelley Zieroth, Kamlesh Khunti, Hiddo Lambers Heerspink, et al

Association Between AID/FID with Incident CV Disease and Mortality

Benedikt Schrage,

The PRESERVED-HF Study – Main Study Presentation and Peer-to-peer Discussion

Mikhail Kosiborod, Dalane W Kitzman,

The PRESERVED-HF Study

Mikhail Kosiborod,

Karl-Heinz Kuck, Gian-Battista Chierchia, Ross Hunter, et al

Stefan Anker, Shelley Zieroth, Andrew JS Coats, et al

ACC 2021: The DARE-19 Randomized Trial

Mikhail Kosiborod,

ACC 2021 Discussion: The LIFE Trial

Harriette Van Spall, Douglas L Mann,

Philippe Pibarot, Patrizio Lancellotti, Jose Luis Zamorano, et al

Shelley Zieroth, Martin R Cowie, Javed Butler, et al

End of Year COVID update with Dr Mikhail Kosiborod and Dr Shelley Zieroth

Mikhail Kosiborod, Shelley Zieroth,

Year End Video With Dr Mikhail Kosiborod And Dr Silvio Inzucchi

Mikhail Kosiborod, Silvio Inzucchi,

Ileana L Piña, Shelley Zieroth,

Andrew JS Coats, Harriette Van Spall, Faiez Zannad, et al

Shelley Zieroth, Stefan Anker,

EASD 2019: The DEFINE-HF trial - Dr Mikhail N Kosiborod

Mikhail Kosiborod,

Media

Stefan Anker, Javed Butler, Antonio Ceriello, et al

Stefan Anker, Javed Butler, Antonio Ceriello, et al

Andrew JS Coats,

Silvio Inzucchi, Andrew JS Coats, Richard Hobbs, et al

Radcliffe & CardioNerds @AHA22: EMPA-Kidney: Empagliflozin & CV Outcomes in Patients with Chronic Kidney Disease

Kate Wilcox, David Preiss,

Watch time: 18m

Paul Kalra,

Watch time: 12m 40s (2 videos)

Christiane Angermann, Javed Butler, Clyde W Yancy, et al

Watch time: 1h 4m (6 videos)

Giuseppe Rosano, Richard Henry P Tiongco, Rungroj Krittayaphong, et al

Piotr Ponikowski, Shelley Zieroth, Javed Butler, et al

Watch time: 1h 3m (4 videos)
HF 22: SCD Risk Protection for Newly Diagnosed HF Patients

José González-Costello,

Andrew JS Coats, Stefan Anker,

Watch Now

Carlos Juanatey,

Watch Now

Stylianos Tzeis,

Watch Now

Yassir Javaid,

Effects of Dapagliflozin in Patients With Chronic Kidney Disease, With and Without Heart Failure

John JV McMurray,

Lars H Lund, James L Januzzi, Justin Ezekowitz, et al

EMPATROPISM FE: Effects of Empagliflozin on iron metabolism in non-diabetic

Christiane Angermann,

Shelley Zieroth, Kamlesh Khunti, Hiddo Lambers Heerspink, et al

Association Between AID/FID with Incident CV Disease and Mortality

Benedikt Schrage,

Kausik Ray, Lale Tokgözoğlu, Maciej Banach, et al

John JV McMurray, Stefan Anker, Melanie Davies, et al

The PRESERVED-HF Study – Main Study Presentation and Peer-to-peer Discussion

Mikhail Kosiborod, Dalane W Kitzman,

The PRESERVED-HF Study

Mikhail Kosiborod,

EP 54: 5 Trials that will change your practice: Review of ESC 21 with Dr Purvi Parwani

Ankur Kalra, Purvi Parwani,

Karl-Heinz Kuck, Gian-Battista Chierchia, Ross Hunter, et al

Stefan Anker, Shelley Zieroth, Andrew JS Coats, et al

ACC 2021: The DARE-19 Randomized Trial

Mikhail Kosiborod,

ACC 2021 Discussion: The LIFE Trial

Harriette Van Spall, Douglas L Mann,

ACC 2021 Discussion: Benefits of SGLT1/2 Inhibition Across the Full Spectrum of EF, Including HFpEF

Deepak L Bhatt, Harriette Van Spall,

Philippe Pibarot, Patrizio Lancellotti, Jose Luis Zamorano, et al

Articles

Pharmacy Challenges in Cardiac Care During COVID-19: Lessons Learnt

Andrew McRae

,

Published:

02 February 2023

Citation:

Cardiac Failure Review 2023;9:e03.

DOI:

https://doi.org/10.15420/cfr.2022.20
  • Views: Views 8
  • Downloads: Downloads 0
  • Read time: 10 Mins

Ranolazine to Improve Diastolic Performance

Desak Ketut Sekar Cempaka Putri

,

Andrianto Andrianto

,

Makhyan Jibril Al-Farabi

,

Pandit Bagus Tri Saputra

,

Ricardo Adrian Nugraha

,

Published:

21 January 2023

Citation:

European Cardiology Review 2023;18:e02.

DOI:

https://doi.org/10.15420/ecr.2022.10
  • Views: Views 235
  • Downloads: Downloads 23
  • Read time: 16 Mins

Polypharmacy in Older People With Heart Failure

Maria Stefil

,

Matthew Dixon

,

Jameela Bahar

,

Schabnam Saied

,

Knievel Mashida

,

Olivia Heron

,

Eduard Shantsila

,

Lauren Walker

,

Asangaedem Akpan

,

Gregory YH Lip

,

Rajiv Sankaranarayanan

,

Published:

19 December 2022

Citation:

Cardiac Failure Review 2022;8:e34.

DOI:

https://doi.org/10.15420/cfr.2022.14
  • Views: Views 544
  • Downloads: Downloads 34
  • Read time: 21 Mins

SGLT2i in HFpEF

Mauro Gori

,

Emilia D’Elia

,

Edoardo Sciatti

,

Michele Senni

,

Published:

08 July 2022

Citation:

Cardiac Failure Review 2022;8:e26.

DOI:

https://doi.org/10.15420/cfr.2022.04
  • Views: Views 2224
  • Downloads: Downloads 216
  • Citations: 2